Possible combination of a drug and immunotherapy tested in ex vivo immune cells
2016
IRCCS Ospedale Pediatrico Bambino Gesù, Roma, Italy(1)
University of Genoa, Genoa, Italy(2)
University of Genoa, Genoa, Italy(2)
Melanoma has an incidence that is increasing at a rate faster than any other solid malignancy. Approximately 50% of cutaneous melanomas harbour a somatic mutation in the gene encoding BRAF, a serine/threonine protein kinase. Therapies based on mutated BRAF- inhibitors have been developed for melanoma treatment. Combined with immunotherapy, they could represent a promising strategy for the cure of melanoma. In the present study, the researchers aimed at clarifying the actual efficacy of combination treatments involving inhibitors and NK cell-based immunotherapy, as well as the occurrence of possible interference with NK cell function. NK cells were isolated from donors and cultured in vitro with different concentrations of BRAF inhibitor to show that there was no effect on the functional properties of NK cells. The data suggest that oncogene-targeting drugs are compatible with NK-based adoptive therapy.
Cytokines can counteract the inhibitory effect of MEK-i on NK-cell function
Lorenzo Moretta(1), Gabriella Pietra(2)
Added on: 09-18-2021
[1] https://www.oncotarget.com/article/11504/text/[2] https://data.jrc.ec.europa.eu/dataset/352f7dfd-05cf-434b-a96a-7e270dc76573
